Antitubercular Medications

Key Points

  • Antitubercular medications are selective for mycobacteria and are used in multidrug regimens for active tuberculosis.
  • Core action patterns include inhibition of mycobacterial RNA transcription and inhibition of mycolic-acid synthesis in the cell wall.
  • Therapy is prolonged (often at least 6 months, and longer in resistant disease), so adherence support is a primary nursing priority.
  • Major safety risks include hepatotoxicity, GI intolerance, peripheral neuropathy, and selected visual changes.
  • Isoniazid and rifampin may reduce oral-contraceptive effectiveness; backup or alternate contraception counseling is required.
  • Directly observed therapy (DOT) improves completion and reduces multidrug-resistant tuberculosis risk.

Class Overview

Antitubercular therapy targets Mycobacterium tuberculosis and is delivered as a combination regimen to reduce resistance emergence. Because treatment duration is long, adherence failures can rapidly drive treatment failure and resistance.

Multidrug-resistant tuberculosis (MDR-TB), including resistance to at least isoniazid and rifampin, requires individualized therapy based on susceptibility testing and close interprofessional coordination.

Prototype Highlights

Isoniazid

  • Common role: First-line component of multidrug TB treatment pathways.
  • Adherence strategy: DOT may be used to support full-course completion.
  • Safety priorities: Monitor for hepatotoxicity and GI intolerance.
  • Neuropathy prevention: Pyridoxine (vitamin B6) supplementation is commonly used to reduce peripheral-neuropathy risk.
  • Teaching points: Reinforce strict adherence even after symptom improvement and counsel on alternate contraception if oral contraceptives are used.

Rifampin

  • Common role: First-line TB regimen component; also used in selected non-TB infection pathways (for example meningococcal prophylaxis).
  • Adherence strategy: DOT may be used in long-course treatment.
  • Safety priorities: Monitor for hepatotoxicity, drowsiness, and GI upset.
  • Distinct counseling point: Body fluids may turn red-orange and can permanently stain soft contact lenses.
  • Teaching points: Reinforce alternate contraception counseling when oral contraceptives are used and immediate reporting of concerning adverse effects.

Nursing Considerations

  • Expect prolonged therapy and verify the patient understands full-course duration before discharge.
  • Monitor liver enzymes and escalate jaundice, right-upper-quadrant pain, dark urine, severe fatigue, or persistent nausea/vomiting.
  • Screen for neuropathy and visual changes during follow-up and report progression promptly.
  • Teach strict alcohol avoidance during therapy because hepatotoxicity risk is increased.
  • Reinforce regimen-specific food cautions when ordered (for example tyramine-rich foods in selected plans).
  • Use structured adherence support (DOT, reminder systems, family support, and follow-up scheduling) to reduce missed doses.
  • Document contraception counseling and backup-method planning when interacting medications are present.

Self-Check

  1. Why is DOT frequently used in antitubercular treatment plans?
  2. Which adverse effects require urgent escalation during isoniazid and rifampin therapy?
  3. What teaching points are required when a patient uses oral contraceptives during TB treatment?